Archive · 15 Jun 2025
EMA Reviews Semaglutide Risk of Eye Condition
Imagine your body has a helpful hormone, GLP-1, that controls sugar.
Semaglutide is like a copy of that hormone, helping people with diabetes and obesity.
It helps lower blood sugar and makes you feel full.
However, the European Medicines Agency (EMA) checked semaglutide because some people using it might get a rare eye problem called NAION, which can cause vision loss.
Studies suggest that taking semaglutide slightly raises this risk.
So, if you're taking semaglutide and your eyesight suddenly gets worse, tell your doctor right away.
The EMA wants to make sure everyone knows about this potential side effect.
EMA reviewed semaglutide due to potential eye condition risk.
Semaglutide is used to treat diabetes and obesity, with brand names like Ozempic.
NAION is a very rare side effect of semaglutide.
Studies show a nearly two-fold NAION risk increase for those taking semaglutide.
EMA recommends updating product information to include NAION as a side effect.
- Who
- The EMA reviewed medicines containing semaglutide, including Ozempic, Rybelsus and Wegovy.
- What
- The EMA reviewed semaglutide medicines regarding the risk of NAION, a rare eye condition.
- When
- The review concluded on June 15, 2025, based on the provided publication date.
- Where
- The review was conducted by the European Medicines Agency (EMA).
- Why
- The review was conducted due to concerns over a potentially increased risk of developing NAION, an eye condition that may cause loss of vision.
Patient Safety Concerns
Pharmaceutical Industry
Risk vs. Benefit
Patient Safety Concerns
Patients may be concerned about the potential for vision loss due to a side effect.
Pharmaceutical Industry
Pharmaceutical companies emphasize the rarity of the side effect in the context of the benefits of the drugs.
- Drug Name
- Semaglutide
- Conditions Treated
- Diabetes and Obesity
- Brand Names
- Ozempic, Rybelsus, Wegovy
- Side Effect
- Non-arteritic anterior ischemic optic neuropathy (NAION)
- Risk Increase
- Nearly two-fold in adults with type 2 diabetes
- Action
- Update product information, advise immediate doctor contact for vision changes
- Frequency
- Very Rare